{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:57:13Z","timestamp":1788472633241,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Outcomes for patients with melanoma have improved over the past decade with the clinical development and approval of immunotherapies targeting immune checkpoint receptors such as programmed death-1 (PD-1), programmed death ligand 1 (PD-L1) or cytotoxic T lymphocyte antigen-4 (CTLA-4). Combinations of these checkpoint therapies with other agents are now being explored to improve outcomes and enhance benefit-risk profiles of treatment. Alternative inhibitory receptors have been identified that may be targeted for anti-tumor immune therapy, such as lymphocyte-activation gene-3 (LAG-3), as have several potential target oncogenes for molecularly targeted therapy, such as tyrosine kinase inhibitors. Unfortunately, many patients still progress and acquire resistance to immunotherapy and molecularly targeted therapies. To bypass resistance, combination treatment with immunotherapies and single or multiple TKIs have been shown to improve prognosis compared to monotherapy. The number of new combinations treatment under development for melanoma provides options for the number of patients to achieve a therapeutic benefit. Many diagnostic and prognostic assays have begun to show clinical applicability providing additional tools to optimize and individualize treatments. However, the question on the optimal algorithm of first- and later-line therapies and the search for biomarkers to guide these decisions are still under investigation. This year, the Melanoma Bridge Congress (Dec 1<jats:sup>st<\/jats:sup>\u20133rd, 2022, Naples, Italy) addressed the latest advances in melanoma research, focusing on themes of paramount importance for melanoma prevention, diagnosis and treatment. This included sessions dedicated to systems biology on immunotherapy, immunogenicity and gene expression profiling, biomarkers, and combination treatment strategies.<\/jats:p>","DOI":"10.1186\/s12967-023-04325-x","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T10:03:17Z","timestamp":1690538597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st\u20133rd, 2022\u2014Naples, Italy)"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv S.","family":"Agarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison Betof","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Ernstoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Galon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Gastman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Gershenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Kalinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Krogsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rom S.","family":"Leidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulikos I.","family":"Poulikakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Carac\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Puzanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Thurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"issue":"14","key":"4325_CR1","doi-asserted-by":"publisher","first-page":"e93652","DOI":"10.1172\/jci.insight.93652","volume":"2","author":"Z Feng","year":"2017","unstructured":"Feng Z, Bethmann D, Kappler M, Ballesteros-Merino C, Eckert A, Bell RB, et al. Multiparametric immune profiling in HPV-oral squamous cell cancer. JCI Insight. 2017;2(14):e93652.","journal-title":"JCI Insight"},{"issue":"18","key":"4325_CR2","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1158\/1078-0432.CCR-22-0404","volume":"28","author":"P Johannet","year":"2022","unstructured":"Johannet P, Liu W, Fenyo D, Wind-Rotolo M, Krogsgaard M, Mehnert JM, et al. Baseline serum autoantibody signatures predict recurrence and toxicity in melanoma patients receiving adjuvant immune checkpoint blockade. Clin Cancer Res. 2022;28(18):4121\u201330.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4325_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjd.21241","volume":"187","author":"X Bai","year":"2022","unstructured":"Bai X, Shoushtari AN, Betof Warner A, Si L, Tang B, Cui C, et al. Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. Br J Dermatol. 2022;187(3):401\u201310.","journal-title":"Br J Dermatol"},{"issue":"2","key":"4325_CR4","doi-asserted-by":"publisher","first-page":"e000948","DOI":"10.1136\/jitc-2020-000948","volume":"8","author":"O Michielin","year":"2020","unstructured":"Michielin O, Atkins MB, Koon HB, Dummer R, Ascierto PA. Evolving impact of long-term survival results on metastatic melanoma treatment. J Immunother Cancer. 2020;8(2):e000948.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4325_CR5","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","volume":"33","author":"T Andr\u00e9","year":"2022","unstructured":"Andr\u00e9 T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022;33(10):1052\u201360.","journal-title":"Ann Oncol"},{"issue":"6","key":"4325_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in checkmate 227. J Clin Oncol. 2023;41(6):1200\u201312.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4325_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785\u201392.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4325_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4(3):374\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4325_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/0284186X.2020.1818823","volume":"60","author":"AH Boekhout","year":"2021","unstructured":"Boekhout AH, Rogiers A, Jozwiak K, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, et al. Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. Acta Oncol. 2021;60(1):69\u201377.","journal-title":"Acta Oncol"},{"issue":"12","key":"4325_CR10","doi-asserted-by":"publisher","first-page":"e50221","DOI":"10.1371\/journal.pone.0050221","volume":"7","author":"B Wolf","year":"2012","unstructured":"Wolf B, Schwarzer A, C\u00f4t\u00e9 AL, Hampton TH, Schwaab T, Huarte E, et al. Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-\u03b1 and dendritic cell vaccine. PLoS ONE. 2012;7(12):e50221.","journal-title":"PLoS ONE"},{"issue":"7","key":"4325_CR11","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00262-020-02833-z","volume":"70","author":"E Naidus","year":"2021","unstructured":"Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, et al. Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients. Cancer Immunol Immunother. 2021;70(7):2095\u2013102.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"4325_CR12","doi-asserted-by":"publisher","first-page":"e006398","DOI":"10.1136\/jitc-2022-006398","volume":"11","author":"J Naidoo","year":"2023","unstructured":"Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023;11(3):e006398.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4325_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u201361.","journal-title":"Nat Med"},{"issue":"2","key":"4325_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27(2):301\u20139.","journal-title":"Nat Med"},{"issue":"2","key":"4325_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27(2):256\u201363.","journal-title":"Nat Med"},{"issue":"6","key":"4325_CR16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178\u201388.","journal-title":"Nat Med"},{"issue":"Suppl 7","key":"4325_CR17","doi-asserted-by":"publisher","first-page":"S908","DOI":"10.1016\/j.annonc.2022.07.923","volume":"33","author":"IULM Reijers","year":"2022","unstructured":"Reijers IULM, Menzies AM, Versluis JM, Dimitriadis P, Wouters M, Saw RPM, et al. Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-\u03b3 sign) algorithm. Ann Oncol. 2022;33(Suppl 7):S908\u20139.","journal-title":"Ann Oncol"},{"issue":"7934","key":"4325_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","volume":"611","author":"RN Amaria","year":"2022","unstructured":"Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611(7934):155\u201360.","journal-title":"Nature"},{"issue":"Suppl_7","key":"4325_CR19","doi-asserted-by":"publisher","first-page":"S808","DOI":"10.1016\/annonc\/annonc1089","volume":"33","author":"S Patel","year":"2022","unstructured":"Patel S, Othus M, Prieto V, Lowe M, Buchbinder E, Chen Y, et al. Neoadjvuant versus adjuvant pembrolizumab for resected stage III\u2013IV melanoma (SWOG S1801). Ann Oncol. 2022;33(Suppl_7):S808\u201369. https:\/\/doi.org\/10.1016\/annonc\/annonc1089.","journal-title":"Ann Oncol"},{"issue":"Suppl_7","key":"4325_CR20","first-page":"S808","volume":"33","author":"JCL Notohardjo","year":"2022","unstructured":"Notohardjo JCL, Veenstra S, Koster BD, Kandiah V, van der Velde S, Francken AB, et al. Intradermal IMO-2125 versus placebo as adjuvant treatment in patients with stage II pT3\u20134\/cN0 melanoma: Interim efficacy and safety results of the randomized phase II INTRIM study. Ann Oncol. 2022;33(Suppl_7):S808\u201369.","journal-title":"Ann Oncol"},{"issue":"6371","key":"4325_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"6575","key":"4325_CR22","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","volume":"374","author":"CN Spencer","year":"2021","unstructured":"Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374(6575):1632\u201340.","journal-title":"Science"},{"key":"4325_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.06.020","volume":"138","author":"AJP Clover","year":"2020","unstructured":"Clover AJP, de Terlizzi F, Bertino G, Curatolo P, Odili J, Campana LG, et al. Electrochemotherapy in the treatment of cutaneous malignancy: outcomes and subgroup analysis from the cumulative results from the pan-European international network for sharing practice in electrochemotherapy database for 2482 lesions in 987 patients (2008\u20132019). Eur J Cancer. 2020;138:30\u201340.","journal-title":"Eur J Cancer"},{"issue":"4","key":"4325_CR24","first-page":"470","volume":"20","author":"CS Claussen","year":"2022","unstructured":"Claussen CS, Moir G, Bechara FG, Orlando A, Matteucci P, Mowatt D, et al. Prospective cohort study by InspECT on safety and efficacy of electrochemotherapy for cutaneous tumors and metastases depending on ulceration. J Dtsch Dermatol Ges. 2022;20(4):470\u201381.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"4325_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1245\/s10434-008-0204-8","volume":"16","author":"LG Campana","year":"2009","unstructured":"Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution\u2019s experience with 52 patients. Ann Surg Oncol. 2009;16(1):191\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4325_CR26","doi-asserted-by":"publisher","first-page":"e1008842","DOI":"10.1080\/2162402X.2015.1008842","volume":"4","author":"N Mozzillo","year":"2015","unstructured":"Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, et al. Assessing a novel immuno-oncology-based combination therapy: ipilimumab plus electrochemotherapy. Oncoimmunology. 2015;4(6):e1008842.","journal-title":"Oncoimmunology"},{"issue":"17","key":"4325_CR27","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.3390\/cancers13174289","volume":"13","author":"LG Campana","year":"2021","unstructured":"Campana LG, Peric B, Mascherini M, Spina R, Kunte C, Kis E, et al. Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma: a comparative retrospective study from the InspECT and slovenian cancer registry. Cancers. 2021;13(17):4289.","journal-title":"Cancers"},{"issue":"4","key":"4325_CR28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/ijc.32172","volume":"145","author":"V Franke","year":"2019","unstructured":"Franke V, Berger DMS, Klop WMC, van der Hiel B, van de Wiel BA, Ter Meulen S, et al. High response rates for T-VEC in early metastatic melanoma (stage IIIB\/C-IVM1a). Int J Cancer. 2019;145(4):974\u20138.","journal-title":"Int J Cancer"},{"issue":"17","key":"4325_CR29","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced unresectable melanoma. J Clin Oncol. 2018;36(17):1658\u201367.","journal-title":"J Clin Oncol"},{"issue":"Suppl_7","key":"4325_CR30","first-page":"S808","volume":"33","author":"R Dummer","year":"2022","unstructured":"Dummer R, Gyorki D, Hyngstrom J, Berger A, Conry R, Demidov L, et al. Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL). Ann Oncol. 2022;33(Suppl_7):S808\u201369.","journal-title":"Ann Oncol"},{"issue":"10135","key":"4325_CR31","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128\u201339.","journal-title":"Lancet"},{"issue":"31","key":"4325_CR32","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.19.03205","volume":"38","author":"B Mlecnik","year":"2020","unstructured":"Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, et al. Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. J Clin Oncol. 2020;38(31):3638\u201351.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4325_CR33","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.annonc.2020.03.310","volume":"31","author":"F Pag\u00e8s","year":"2020","unstructured":"Pag\u00e8s F, Andr\u00e9 T, Taieb J, Vernerey D, Henriques J, Borg C, et al. Prognostic and predictive value of the immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020;31(7):921\u20139 (Erratum in: Ann Oncol, 2020;31(9):1276).","journal-title":"Ann Oncol"},{"issue":"2","key":"4325_CR34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/cancers15020418","volume":"15","author":"B Mlecnik","year":"2023","unstructured":"Mlecnik B, Lugli A, Bindea G, Marliot F, Bifulco C, Lee JJ, et al. Multicenter international study of the consensus immunoscore for the prediction of relapse and survival in early-stage colon cancer. Cancers. 2023;15(2):418.","journal-title":"Cancers"},{"issue":"1","key":"4325_CR35","doi-asserted-by":"publisher","first-page":"2161167","DOI":"10.1080\/2162402X.2022.2161167","volume":"12","author":"F Wang","year":"2023","unstructured":"Wang F, Lu S, Cao D, Qian J, Li C, Zhang R, et al. Prognostic and predictive value of immunoscore and its correlation with ctDNA in stage II colorectal cancer. Oncoimmunology. 2023;12(1):2161167.","journal-title":"Oncoimmunology"},{"issue":"19","key":"4325_CR36","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-20-0337","volume":"26","author":"C El Sissy","year":"2020","unstructured":"El Sissy C, Kirilovsky A, Van den Eynde M, Mu\u015fin\u0103 AM, Anitei MG, Romero A, et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy. Clin Cancer Res. 2020;26(19):5198\u2013207.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4325_CR37","doi-asserted-by":"publisher","first-page":"e27456","DOI":"10.4161\/onci.27456","volume":"3","author":"G Bindea","year":"2014","unstructured":"Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology. 2014;3(1):e27456. https:\/\/doi.org\/10.4161\/onci.27456.","journal-title":"Oncoimmunology"},{"issue":"9","key":"4325_CR38","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022;28(9):1872\u201382.","journal-title":"Nat Med"},{"issue":"7","key":"4325_CR39","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23(7):876\u201387.","journal-title":"Lancet Oncol"},{"issue":"13","key":"4325_CR40","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.21.01601","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, et al. Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma. J Clin Oncol. 2022;40(13):1428\u201338.","journal-title":"J Clin Oncol"},{"issue":"10240","key":"4325_CR41","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835\u201344.","journal-title":"Lancet"},{"issue":"2","key":"4325_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127\u201337.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4325_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"issue":"Suppl_7","key":"4325_CR44","first-page":"356","volume":"33","author":"A Diab","year":"2022","unstructured":"Diab A, Gogas HJ, Sandhu SK, Long GV, Ascierto PA, Larkin J, et al. PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL). Ann Oncol. 2022;33(Suppl_7):356\u2013409.","journal-title":"Ann Oncol"},{"key":"4325_CR45","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3389\/fimmu.2018.00164","volume":"9","author":"G Qiao","year":"2018","unstructured":"Qiao G, Chen M, Bucsek MJ, Repasky EA, Hylander BL. Adrenergic signaling: a targetable checkpoint limiting development of the antitumor immune response. Front Immunol. 2018;9:164.","journal-title":"Front Immunol"},{"issue":"1","key":"4325_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00262-018-2243-8","volume":"68","author":"G Qiao","year":"2019","unstructured":"Qiao G, Bucsek MJ, Winder NM, Chen M, Giridharan T, Olejniczak SH, et al. \u03b2-Adrenergic signaling blocks murine CD8+ T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress. Cancer Immunol Immunother. 2019;68(1):11\u201322.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"4325_CR47","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1158\/2326-6066.CIR-20-0445","volume":"9","author":"G Qiao","year":"2021","unstructured":"Qiao G, Chen M, Mohammadpour H, MacDonald CR, Bucsek MJ, Hylander BL, et al. Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment. Cancer Immunol Res. 2021;9(6):651\u201364.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4325_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1078-0432.CCR-20-2381","volume":"27","author":"S Gandhi","year":"2021","unstructured":"Gandhi S, Pandey MR, Attwood K, Ji W, Witkiewicz AK, Knudsen ES, et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity. Clin Cancer Res. 2021;27(1):87\u201395.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4325_CR49","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","volume":"40","author":"Y Hailemichael","year":"2022","unstructured":"Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509\u201323.","journal-title":"Cancer Cell"},{"issue":"1","key":"4325_CR50","doi-asserted-by":"publisher","first-page":"e000842","DOI":"10.1136\/jitc-2020-000842","volume":"8","author":"AS Laino","year":"2020","unstructured":"Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, Weber J. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020;8(1):e000842.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4325_CR51","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25(3):551\u20137.","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl_5","key":"4325_CR52","first-page":"S867","volume":"32","author":"JS Weber","year":"2021","unstructured":"Weber JS, Muramatsu T, Hamid O, Mehnert J, Hodi FS, Krishnarajapet S, et al. Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma. Ann Oncol. 2021;32(Suppl_5):S867\u2013905.","journal-title":"Ann Oncol"},{"issue":"Supp 1","key":"4325_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100263","volume":"16","author":"EJJ Montazari","year":"2022","unstructured":"Montazari EJJ, Abdel-Wahab N, Johnson D, Spillson C, Elsayes KM, Duan F, et al. Clinical outcome and preliminary immune analysis of phase II clinical trial of combination of tocilizumab with ipilimumab and nivolumab for patients with treatment na\u00efve metastatic melanoma. Immuno-Oncol Technol. 2022;16(Supp 1): 100263.","journal-title":"Immuno-Oncol Technol"},{"issue":"4","key":"4325_CR54","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","volume":"27","author":"A Montfort","year":"2021","unstructured":"Montfort A, Filleron T, Virazels M, Dufau C, Milh\u00e8s J, Pag\u00e8s C, et al. Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial. Clin Cancer Res. 2021;27(4):1037\u201347.","journal-title":"Clin Cancer Res"},{"key":"4325_CR55","doi-asserted-by":"crossref","unstructured":"Finnigan J, Newman J, Patskovsky Y, Patskovska L, Ishizuka A, Lynn G, et al. Structural basis for self-discrimination by neoantigen-specific TCRs. Res Sq [Preprint]. 2023 Jan 31:rs.3.rs-2531184","DOI":"10.21203\/rs.3.rs-2531184\/v1"},{"key":"4325_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2019.10.027","volume":"125","author":"TMS Amaral","year":"2020","unstructured":"Amaral TMS, Hoffmann MC, Sinnberg T, Niessner H, S\u00fclberg H, Eigentler TK, Garbe C. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. Eur J Cancer. 2020;125:38\u201345.","journal-title":"Eur J Cancer"},{"issue":"5","key":"4325_CR57","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/bjd.19499","volume":"184","author":"EEAP Mulder","year":"2021","unstructured":"Mulder EEAP, Dwarkasing JT, Tempel D, van der Spek A, Bosman L, Verver D, et al. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma. Br J Dermatol. 2021;184(5):944\u201351.","journal-title":"Br J Dermatol"},{"issue":"9","key":"4325_CR58","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1001\/jamadermatol.2020.1729","volume":"156","author":"D Grossman","year":"2020","unstructured":"Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, et al. Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit. JAMA Dermatol. 2020;156(9):1004\u201311.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"4325_CR59","doi-asserted-by":"publisher","first-page":"e20202084","DOI":"10.1084\/jem.20202084","volume":"219","author":"C Li","year":"2022","unstructured":"Li C, Phoon YP, Karlinsey K, Tian YF, Thapaliya S, Thongkum A, et al. A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. J Exp Med. 2022;219(1):e20202084.","journal-title":"J Exp Med"},{"issue":"24","key":"4325_CR60","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy metastatic melanoma. J Clin Oncol. 2021;39(24):2656\u201366.","journal-title":"J Clin Oncol"},{"issue":"Suppl_7","key":"4325_CR61","first-page":"S808","volume":"33","author":"JBAG Haanen","year":"2022","unstructured":"Haanen JBAG, Rohaan M, Borch TH, van den Bergn JH, Met \u00d6, Geukes Foppen M, et al. Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: results from a multicenter, randomized phase III trial. Ann Oncol. 2022;33(Suppl_7):S808\u201369.","journal-title":"Ann Oncol"},{"issue":"20","key":"4325_CR62","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1158\/1078-0432.CCR-16-2677","volume":"23","author":"DJ Messenheimer","year":"2017","unstructured":"Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin Cancer Res. 2017;23(20):6165\u201377.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4325_CR63","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s40425-019-0786-7","volume":"7","author":"JM Patel","year":"2019","unstructured":"Patel JM, Cui Z, Wen ZF, Dinh CT, Hu HM. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism. J Immunother Cancer. 2019;7(1):311.","journal-title":"J Immunother Cancer"},{"key":"4325_CR64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0422","author":"BA Fox","year":"2023","unstructured":"Fox BA, Urba WJ, Jensen SM, Page DB, Curti BD, Sanborn RE, Leidner RS. Cancer\u2019s dark matter: lighting the abyss unveils universe of new therapies. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0422.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4325_CR65","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","volume":"29","author":"H Okada","year":"2011","unstructured":"Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330\u20136.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4325_CR66","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1172\/JCI68395","volume":"123","author":"BM Carreno","year":"2013","unstructured":"Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest. 2013;123(8):3383\u201394.","journal-title":"J Clin Invest"},{"issue":"16","key":"4325_CR67","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/1078-0432.CCR-17-2707","volume":"24","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, et al. Cytokines produced by dendritic cells administered intratumorally correlate with clinical outcome in patients with diverse cancers. Clin Cancer Res. 2018;24(16):3845\u201356.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4325_CR68","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","volume":"26","author":"RA Figlin","year":"2020","unstructured":"Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, et al. Results of the ADAPT phase 3 study of rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2020;26(10):2327\u201336.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4325_CR69","doi-asserted-by":"publisher","first-page":"e003675","DOI":"10.1136\/jitc-2021-003675","volume":"9","author":"WJ Storkus","year":"2021","unstructured":"Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, et al. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021;9(11):e003675.","journal-title":"J Immunother Cancer"},{"issue":"15","key":"4325_CR70","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1158\/0008-5472.CAN-17-3985","volume":"78","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN, Yerneni S, Sarkar SN, Orr B, Muthuswamy R, Voyten J, et al. Helicase-driven activation of NF\u03baB-COX2 pathway mediates the immunosuppressive component of dsRNA-driven inflammation in the human tumor microenvironment. Cancer Res. 2018;78(15):4292\u2013302.","journal-title":"Cancer Res"},{"issue":"7","key":"4325_CR71","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1158\/2159-8290.CD-20-1351","volume":"11","author":"C Adamopoulos","year":"2021","unstructured":"Adamopoulos C, Ahmed TA, Tucker MR, Ung PMU, Xiao M, Karoulia Z, et al. Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling. Cancer Discov. 2021;11(7):1716\u201335.","journal-title":"Cancer Discov"},{"issue":"1","key":"4325_CR72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-022-01330-3","volume":"15","author":"M Elnaggar","year":"2022","unstructured":"Elnaggar M, Agte S, Restrepo P, Ram M, Melnekoff D, Adamopoulos C, et al. Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation. J Hematol Oncol. 2022;15(1):109.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4325_CR73","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186\u201397.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4325_CR74","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Mandal\u00e0 M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-Arm, open-label phase II trial. J Clin Oncol. 2023;41(2):212\u201321.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4325_CR75","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","volume":"23","author":"GV Long","year":"2022","unstructured":"Long GV, Luke JJ, Khattak MA, de la Cruz ML, Del Vecchio M, Rutkowski P, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022;23(11):1378\u201388.","journal-title":"Lancet Oncol"},{"key":"4325_CR76","unstructured":"Long GV. Adjuvant therapy with nivolumab versus placebo in patients with stage IIB\/C melanoma (CheckMate 76K). Presented at the 2022 Society for Melanoma Research (SMR) Annual Meeting October 17\u201320. Edinburgh, UK. 2022."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04325-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04325-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04325-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T10:06:29Z","timestamp":1690538789000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04325-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4325"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04325-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"19 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Paolo A. Ascierto (PAA): <i>Employment or Leadership Position<\/i>: None; <i>Consultant\/Advisory Role<\/i>: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna; <i>Stock Ownership<\/i>: None; <i>Research Funding<\/i>: Bristol-Meyers Squibb, Roche-Genentech, Pfizer, Sanofi; <i>Expert Testimony<\/i>: None; <i>Other Remuneration<\/i>: None. Sanjiv S. Agarwala (SSA):\u00a0nothing to disclose. Allison Betof Warner (ABW): <i>Consulting or Advisory<\/i>: Iovance Biotherapeutics, Novartis, BluePath Solutions, Pfizer, Instil Bio, Lyell Immunopharma, Bristol-Myers Squibb\/Medarex, Immatics; <i>Research Funding:<\/i> Iovance Biotherapeutics; <i>Travel, Accommodations, Expenses:<\/i> Iovance Biotherapeutic. Marc S. Ernstoff (MSE):\u00a0no conflict to disclose. Bernard A. Fox (BAF): <i>Scientific Advisory Board (Advising\/Consulting)<\/i>: Akoya\/PerkinElmer, AstraZeneca\/Definiens, Bristol-Myers Squibb, CanWell, Hookipa, Incyte, Macrogenics, NeoGenomics, PrimeVax (BOD, stock), Turnstone, UbiVac, Co-founder\/CEO\/stock, Ultivue; <i>Research Support<\/i>: Akoya\/PerkinElmer, Bristol-Myers Squibb, Definies\/AstraZeneca, Incyte, Macrogenics, NanoString, OncoSec Shimadzu, Viralytics\/Merck. Thomas F. Gajewski (TFG):\u00a0<i>Consultant\/advisory boards<\/i>: Merck, Bayer, Jounce, Fog Pharma,\u00a0Adaptimmune,\u00a0Pyxis,\u00a0Allogene,\u00a0Catalym,\u00a0Bicara, Samyang; <i>Research support<\/i>: BMS, Merck, Seattle Genetics,\u00a0Evelo,Bayer,\u00a0Aduro,\u00a0Pyxis; <i>Intellectual property\/licensing<\/i>: Aduro,\u00a0Evelo, BMS; <i>Cofounder\/shareholder:<\/i> Jounce, Pyxis. J\u00e9r\u00f4me Galon (JG): has patents associated with the immune prognostic biomarkers. JG is co-founder of HalioDx, a Veracyte company, and part-time employee of Veracyte.\u202fImmunoscore\u00ae\u202fa registered trademark owned by the National Institute of Health and Medical Research (INSERM) and licenced to\u202fVeracyte. Claus Garbe (CG): personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from NeraCare, personal fees from BMS, personal fees from Philogen, grants and personal fees from Sanofi, during the conduct of the study. Brian R. Gastman (BRG): consulting agreements with: Quest imaging, Castle Biosciences, Merck, BMS, Alkermes, NIT, Instill Bio and Iovance. Jeffrey E. Gershenwald (JEG): Consultant and\/or advisory role: Merck, Regeneron, Syndax. Pawel Kalinski (PW):\u00a0Ikena; Mersana; Molecular Templates; Immunicum. Michelle Krogsgaard (MK): <i>Consultant for:<\/i> Guidepoint Network and GLG; <i>Grant\/Research support from<\/i>: Agenus, AgenTus Therapeutics, Inc., Merck & Company, Inc., Genentech\/Roche, Biogen, Novartis; <i>Scientific Advisory Board member<\/i>: NexImmune. Rom S. Leidner (RSL): Incyte\u00a0&\u00a0Ubivac: support of\u00a0this\u00a0study; Celldex: research; Clinigen: research; Bristol-Myers-Squibb: research, travel,\u00a0advisory. Roger S. Lo (RSLO):\u00a0Pfizer (investigator initiated\u00a0trial, honorarium); Merck,\u00a0OncoSec\u00a0(research funding); Pfizer,\u00a0DayOne\u00a0(research funding, pending). Alexander M. Menzies (AMM): has served on advisory boards for BMS, MSD, Novartis, Roche, Pierre Fabre, QBiotics. Olivier Michielin (OM):\u00a0Personal financial interests:\u00a0Honoraria as speaker, consultancy or advisory\u00a0role:\u00a0BMS, Roche, Amgen, MSD, Novartis, GSK,\u00a0Pierre-Fabre; Stock ownership: None; Direct Research Funding: BMS, MSD, Merk and\u00a0Amgen\u200b. Institutional financial interests: Research Funding: BMS, MSD and Amgen. Poulikos I. Poulikakos (PIP):\u00a0research funding from Black Diamond\u00a0Therapeutics, Verastem\u00a0Onc. Jeffrey S. Weber (JSW): I consult for Merck, Genentech, Astra Zeneca, GSK, Novartis, Nektar, Celldex, Incyte, Biond, Moderna, ImCheck, Sellas, Evaxion, Pfizer, Regeneron and EMD Serono and BMS for membership on Advisory Boards; I hold equity in Biond, Evaxion, OncoC4 and Instil Bio. I am on scientific advisory boards for CytoMx, Incyte, ImCheck, Biond, Sellas, Instil Bio OncoC4 and Neximmune; I am not a member of any speaker\u2019s bureau; NYU, but not me personally, received research support from BMS, Merck, GSK, Moderna, Pfizer, Novartis and Astra Zeneca; Moffitt Cancer Center filed a patent on an IPILIMUMAB biomarker and on TIL preparation that I am named on, and Biodesix filed a PD-1 patent that I was named on. Corrado Carac\u00f2 (CC): no conflict to disclose. Iman Osman (IO): no conflict to disclose. Igor Puzanov (IP): <i>Research Funding:<\/i> NIH\/NCI P30CA016056 Cancer Center Support Grant Program Leader, 1.2 Calendar Months; Co<i>Csulting\/Advisory<\/i>: Nouscom, Iovance, Nektar, Regeneron. Magdalena Thurin (MT):\u00a0no conflict to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"508"}}